Search for:

  
About NPCIn the NewsResources and PublicationsNewsroomQuestions & Answers


Contact Us 
Receive Updates 
Links 
Home 

Resources & Publications

By Title
(Alphabetical)


By Audience

By Disease

By Specific Issue Areas

 

Aging

Cultural Diversity

Direct-to-
Consumer Advertising


Disease Management and Medicaid Health Outcomes Management

Drawbacks of Component Management

Drug Spending Trends

Evidence-Based Medicine (EBM)

Ensuring Quality of Care

Individualized Care

Medicaid Pharmaceutical Plan Resources

Medication Compliance

Value of Pharmaceuticals

Request NPC Publications

New Publication Notification

Permissions Request

Resources & Publications

Issue Area - Evidence-Based Medicine (EBM)

EBM Landscape Analysis

This reference guide identifies and documents all relevant organizations, activities, proposals, and key individuals associated with the evidence movement in the U.S., including anything of note under the rubric of evidence-based medicine (EBM), comparative effectivess, health (or medical) technology assessment (HTA), etc.

Full report (April 2008)

NICE: How does it work and what are the implications for the U.S.?

Executive Summary (April 2008)

Full report (April 2008)

This 4-part project examines the National Institute for Health and Clinical Excellence (NICE) and its operations, and the implications for comparative effectiveness reviews in the U.S.

  • Part 1 entails a non-technical overview of NICE, encompassing its governance and organization, topic selection procedures, evidence requirements and assessment methods, and guidance dissemination and implementation.
  • Part 2 provides an in-depth investigation of evidence requirements and assessment methods.
  • Part 3 involves an analysis of public comments on NICE submitted to the House of Commons Health Select Committee, focusing on key stakeholder perspectives on the appraisal process and broader NICE operations.
  • Part 4 examines NICE procedures and standards in the context of the U.S. landscape, and identifies those factors or forces unique to the U.S. marketplace, in comparison to the U.K. and other EU Member States, where applicable.